Ligand Pharmaceuticals (LGND)
(Delayed Data from NSDQ)
$106.39 USD
+0.50 (0.47%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $106.36 -0.03 (-0.03%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$106.39 USD
+0.50 (0.47%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $106.36 -0.03 (-0.03%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Biohaven (BHVN) Stock up 8% on Encouraging Pipeline Updates
by Zacks Equity Research
At its R&D Day, Biohaven (BHVN) provides updates on its pipeline. It also announced submission of a regulatory filing seeking approval for troriluzole in SCA3, an ultra-rare disorder.
Bristol Myers' (BMY) Lung Cancer Drug NDA Gets Priority Review
by Zacks Equity Research
Bristol Myers' (BMY) NDA for repotrectinib for treating patients with NSCLC receives Priority Review from the FDA.
Here's Why Investors Should Hold Universal Health (UHS) Now
by Zacks Equity Research
Universal Health (UHS) benefits from growing patient volumes, sound segmental performance and a solid capital position.
Novo Nordisk (NVO) Growth Hormone Drug Gets Positive CHMP Opinion
by Zacks Equity Research
Novo Nordisk (NVO) gets CHMP recommendation approval for Sogroya for expanded use in children and adolescents with growth hormone deficiency.
Bristol Myers (BMY) Thrombosis Drug Gets Fast Track Designation
by Zacks Equity Research
Bristol Myers (BMY) obtains Fast Track Designation from the FDA for milvexian, which is being developed in collaboration with Johnson and Johnson's Janssen.
Novo Nordisk (NVO) Collaborates for Gene-Editing Therapies
by Zacks Equity Research
Novo Nordisk (NVO) partners with Life Edit Therapeutics to discover and develop gene-editing therapies for rare and cardiometabolic diseases.
Wall Street Analysts Think Ligand (LGND) Could Surge 44.42%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Ligand (LGND) points to a 44.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Has Anebulo Pharmaceuticals (ANEB) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Anebulo Pharmaceuticals, Inc. (ANEB) and Ligand Pharmaceuticals (LGND) have performed compared to their sector so far this year.
Novo Nordisk (NVO) Announces Positive Obesity Program Data
by Zacks Equity Research
Novo Nordisk's (NVO) late-stage study of once-daily oral semaglutide 25 mg and 50 mg in obesity shows superior weight loss at week 68 compared with placebo.
Bristol Myers (BMY) Reports Pulmonary Fibrosis Study Results
by Zacks Equity Research
Bristol Myers' (BMY) idiopathic pulmonary fibrosis drug reduces the rate of lung function decline in a phase II study.
Novartis (NVS) Up 10.8% YTD on Strong Q1, Pipeline Progress
by Zacks Equity Research
Novartis (NVS) gains 10.6% year to date on strong first-quarter results and encouraging data on Kisqali from the NATALEE study.
Bausch (BHC) Gains on Court Ruling for Xifaxan Against Norwich
by Zacks Equity Research
Bausch (BHC) obtains a positive ruling for one of its top drugs, Xifaxan, against Norwich from the U.S. District Court of Delaware. Stock up in response to the same.
Viking (VKTX) Up 12% as VKTX-2809 Meets Goals in NASH Study
by Zacks Equity Research
A mid-stage study data shows that Viking Therapeutics' (VKTX) VK2809 achieved reductions in liver fat content in patients with biopsy-confirmed NASH, following 12-weeks of treatment.
Here's Why Biogen (BIIB) Stock is Up 12.6% This Year So Far
by Zacks Equity Research
Biogen (BIIB) is set to launch three potential new drugs across four indications in 2023, all in areas of high unmet need.
Load Up on These 5 Exceptional Relative Price Strength Stocks
by Nilanjan Choudhury
IDCC, TMHC, NXT, GRBK and LGND are five stocks with explosive relative price strength.
ImmunoGen (IMGN) Stock Surges 230% in a Month: Here's Why
by Zacks Equity Research
ImmunoGen (IMGN) shares surge exponentially in the past month owing to the positive data on the expansion study of Elahere for ovarian cancer. An encouraging initial sales uptake of its first marketed product, Elahere, also contribute to the surge.
FDA Rejects ImmunityBio's (IBRX) Bladder Cancer Therapy Filing
by Zacks Equity Research
FDA rejects ImmunityBio's (IBRX) filing seeking approval of Anktiva (N-803) as a combo-therapy in bladder cancer indication, citing deficiencies in an inspection of contract manufacturing firms.
Intercept (ICPT) Gains 26.2% YTD: What's in Store?
by Zacks Equity Research
Intercept (ICPT) has been having a good run in the year so far, but investors are wary ahead of the upcoming advisory meeting by the FDA's Gastrointestinal Drugs Advisory Committee to review its NDA seeking approval of OCA in steatohepatitis (NASH).
Jazz (JAZZ) Lags on Q1 Earnings & Sales, Reaffirms '23 View
by Zacks Equity Research
Jazz (JAZZ) reports dismal first-quarter results as earnings and sales miss expectations. The company reaffirms its financial guidance for 2023.
Exelixis (EXEL) Q1 Earnings Miss, Revenues Increase Y/Y
by Zacks Equity Research
Exelixis (EXEL) misses first quarter 2023 earnings and sales estimates, but product sales increase year over year.
bluebird (BLUE) Posts Q1 Earnings, Focuses on Zynteglo, Skysona
by Zacks Equity Research
bluebird bio (BLUE) delivers earnings of 21 cents per share in the first quarter, due to a one-time gain. Revenues increase year over year.
Novavax (NVAX) Q1 Earnings Lag, Stock Up 28% on Upbeat '23 View
by Zacks Equity Research
Novavax (NVAX) reports dismal Q1 earnings results, as earnings and revenues miss estimates. However, shares rise on the back of encouraging 2023 guidance and cost-reduction initiatives.
Denali (DNLI) Q1 Earnings Miss Estimates, Pipeline in Focus
by Zacks Equity Research
Denali (DNLI) delivers a wider Q1 loss while collaboration revenues surpass estimates.
Viatris (VTRS) Q1 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
Viatris (VTRS) beats on Q1 earnings but misses sales. The company is now looking to reshape its business after selling its biosimilars portfolio.
Ligand (LGND) Up 3% on Raised '23 View, Beats on Q1 Earnings
by Zacks Equity Research
Ligand Pharmaceuticals (LGND) announces better-than-expected results in first-quarter 2023. Management raises 2023 financial outlook.